EUVIMEDEUVIMED entdecken
Crossref

Efficacy and safety of glecaprevir/pibrentasvir treatment in Koreans with chronic hepatitis C: A retrospective study

Byung Soo Kwan, Sung Min Kong, Sang Goon Shim, Kwang Min Kim, Gil Jong Yu, Jae Jin Lee, Jin Dong Kim

Arab Journal of Gastroenterology · 2023

DOI: 10.1016/j.ajg.2023.01.006 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Arab Journal of Gastroenterology, 2023. Verfasst von Byung Soo Kwan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, 158, Paryong-ro, Masanhoewon-gu, Changwon-si,…. Hauptthemen laut MEDLINE: Antiviral Agents, Hepatitis C, Chronic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND STUDY AIMS: The introduction of direct-acting antiviral (DAA) drugs has dramatically improved chronic hepatitis C (CHC) treatment. The pangenotype DAA therapy glecaprevir/pibrentasvir (G/P) was recently recommended for treating CHC in Korea. Unfortunately, given its recent introduction, little real-world data from a Korean population exists. We examined the effectiveness and safety of G/P treatment in Koreans with CHC. PATIENTS AND METHODS: We analyzed CHC patients at Samsung Changwon Hospital from June 2018 to December 2020. Sustained virologic response at 12 weeks posttreatment (SVR 12) was evaluated after treatment, and the associated factors were analyzed. Furthermore, the degree of liver fibrosis before and after treatment was compared to determine whether liver fibrosis improved. RESULTS: In total, 102 patients were enrolled; 35.3 % had compensated liver cirrhosis (LC), and 11.8 % had received previous treatment. Of the 102 patients, 99 (97.1 %) reached SVR 12. Of the 81 patients who completed 8 weeks of G/P treatment, 80 (98.8 %) reached SVR 12, while 19 of the 21 (90.5 %) patients in the 12- or 16-week group reached SVR 12, with no significant difference between the two groups (P = 0.107). As a secondary endpoint, liver fibrosis before and after treatment was also compared. The Fibrosis-4 index (FIB-4) (3.3 vs 2.8, P = 0.010), aspartate transaminase (AST)-platelet ratio index (APRI) (1.3 vs 1.0, P < 0.001), and liver stiffness measurements (LSM) (9.5 vs 4.6, P < 0.001) were significantly different after G/P treatment. CONCLUSIONS: Regardless of genotype, G/P treatment for Koreans with CHC is safe, highly effective, and can improve liver fibrosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsHepatitis C, ChronicHumansEast Asian PeopleGenotypeLiver CirrhosisRetrospective StudiesAminoisobutyric AcidsCyclopropanesLeucineProlineQuinoxalinesSulfonamidesLactams, MacrocyclicBenzimidazolesPyrrolidines

Stichwörter der Autor:innen

Chronic hepatitis CGlecaprevir/pibrentasvirHepatitis C virusLiver fibrosis

Substanzen

Antiviral AgentsglecaprevirAminoisobutyric AcidsCyclopropanesLeucineProlineQuinoxalinesSulfonamidesLactams, Macrocyclicpibrentasvir

Autor:innen und Institutionen

  • Department of Internal Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, 158, Paryong-ro, Masanhoewon-gu, Changwon-si, Gyeongsangnam-do, Republic of Korea. Electronic address: kbs2459@nave…
  • Department of Internal Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, 158, Paryong-ro, Masanhoewon-gu, Changwon-si, Gyeongsangnam-do, Republic of Korea. Electronic address: biggieman@na…
  • Department of Internal Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, 158, Paryong-ro, Masanhoewon-gu, Changwon-si, Gyeongsangnam-do, Republic of Korea. Electronic address: Sgshim218@na…
  • Department of Internal Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, 158, Paryong-ro, Masanhoewon-gu, Changwon-si, Gyeongsangnam-do, Republic of Korea. Electronic address: argonkim@gma…
  • Department of Internal Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, 158, Paryong-ro, Masanhoewon-gu, Changwon-si, Gyeongsangnam-do, Republic of Korea. Electronic address: mike4u@naver…
  • Department of Internal Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, 158, Paryong-ro, Masanhoewon-gu, Changwon-si, Gyeongsangnam-do, Republic of Korea. Electronic address: blackish@nav…

Zitieren

APA

Kwan, B. S., Kong, S. M., Shim, S. G., Kim, K. M., Yu, G. J., Lee, J. J., & Kim, J. D. (2023). Efficacy and safety of glecaprevir/pibrentasvir treatment in Koreans with chronic hepatitis C: A retrospective study. Arab Journal of Gastroenterology. https://doi.org/10.1016/j.ajg.2023.01.006

Vancouver

Kwan BS, Kong SM, Shim SG, Kim KM, Yu GJ, Lee JJ, et al. Efficacy and safety of glecaprevir/pibrentasvir treatment in Koreans with chronic hepatitis C: A retrospective study. Arab Journal of Gastroenterology. 2023. doi:10.1016/j.ajg.2023.01.006

BibTeX
@article{Kwan2023,
  author = {Kwan, Byung Soo and Kong, Sung Min and Shim, Sang Goon and Kim, Kwang Min and Yu, Gil Jong and Lee, Jae Jin and Kim, Jin Dong},
  title = {Efficacy and safety of glecaprevir/pibrentasvir treatment in Koreans with chronic hepatitis C: A retrospective study},
  journal = {Arab Journal of Gastroenterology},
  year = {2023},
  doi = {10.1016/j.ajg.2023.01.006}
}
Kostenlos starten →